Cardiac Biomarker Increase Associated with Higher Risk of Heart Disease
By LabMedica International staff writers Posted on 30 Jun 2016 |
Image: The Elecsys 2010 immunology analyzer (Photo courtesy of Roche Diagnostics).
High-sensitivity cardiac troponin T (hs-cTnT), a protein that can be measured via a blood test, is a biomarker of cardiovascular risk and cardiac troponin is critical to the clinical diagnosis of heart attack, particularly among symptomatic persons with chest pain.
Detectable concentrations of high-sensitivity troponin, which indicate cardiomyocyte cell damage or death, are known to be present in a substantial proportion of asymptomatic adults without any history of cardiovascular disease; however, little is known about the implications of temporal change in hs-cTnT.
Scientists at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA) and their colleagues performed a prospective observational cohort study, from January 1, 1990, to December 31, 2011, which included 8,838 biracial participants who were initially free of coronary heart disease (CHD) and heart failure (HF) and who had hs-cTnT measured twice, six years apart. Data analysis was performed from October 28, 2014, to March 9, 2016.
The first hs-cTnT level was measured in stored serum samples from visit two in 2012-2013 using a sandwich immunoassay method with a Roche Elecsys 2010 Analyzer (Roche Diagnostics, Indianapolis, IN, USA). The second hs-cTnT level was measured in stored supernatant plasma samples from visit four in 2010 using an electrochemiluminescence immunoassay implemented on a Roche Cobas e411 analyzer. Other tests included highly sensitive C-reactive protein, serum creatinine, and N-terminal pro–brain natriuretic peptide (NT-proBN).
Of the 8,838 participants (mean age, 56 years; 5,215 female (59.0%); 1,891 black (21.4%) there were 1,157 CHD events, 965 HF events, and 1,813 deaths overall. Incident detectable hs-cTnT, baseline, less than 0.005 ng/mL; follow-up, greater than 0.005 ng/mL, was independently associated with subsequent CHD, HF and death relative to an hs-cTnT level less than 0.005 ng/mL at both visits. Individuals with the most marked hs-cTnT increases, those whose baseline was less than 0.005 ng/mL but the follow-up was equal to or greater than 0.014 ng/mL, had significantly increased risks for CHD, HF and death.
The authors concluded that temporal increases in hs-cTnT, is suggestive of progressive myocardial damage, and are independently associated with incident CHD, death, and, above all, HF. Serial determination of hs-cTnT trajectory adds clinically relevant information to baseline testing and may be useful in prognostic assessments and the targeting of prevention strategies to high-risk individuals, especially among persons with stage A or B HF. The study was published on June 8, 2016, in the journal JAMA Cardiology.
Related Links:
Johns Hopkins Bloomberg School of Public Health
Roche Diagnostics
Detectable concentrations of high-sensitivity troponin, which indicate cardiomyocyte cell damage or death, are known to be present in a substantial proportion of asymptomatic adults without any history of cardiovascular disease; however, little is known about the implications of temporal change in hs-cTnT.
Scientists at the Johns Hopkins Bloomberg School of Public Health (Baltimore, MD, USA) and their colleagues performed a prospective observational cohort study, from January 1, 1990, to December 31, 2011, which included 8,838 biracial participants who were initially free of coronary heart disease (CHD) and heart failure (HF) and who had hs-cTnT measured twice, six years apart. Data analysis was performed from October 28, 2014, to March 9, 2016.
The first hs-cTnT level was measured in stored serum samples from visit two in 2012-2013 using a sandwich immunoassay method with a Roche Elecsys 2010 Analyzer (Roche Diagnostics, Indianapolis, IN, USA). The second hs-cTnT level was measured in stored supernatant plasma samples from visit four in 2010 using an electrochemiluminescence immunoassay implemented on a Roche Cobas e411 analyzer. Other tests included highly sensitive C-reactive protein, serum creatinine, and N-terminal pro–brain natriuretic peptide (NT-proBN).
Of the 8,838 participants (mean age, 56 years; 5,215 female (59.0%); 1,891 black (21.4%) there were 1,157 CHD events, 965 HF events, and 1,813 deaths overall. Incident detectable hs-cTnT, baseline, less than 0.005 ng/mL; follow-up, greater than 0.005 ng/mL, was independently associated with subsequent CHD, HF and death relative to an hs-cTnT level less than 0.005 ng/mL at both visits. Individuals with the most marked hs-cTnT increases, those whose baseline was less than 0.005 ng/mL but the follow-up was equal to or greater than 0.014 ng/mL, had significantly increased risks for CHD, HF and death.
The authors concluded that temporal increases in hs-cTnT, is suggestive of progressive myocardial damage, and are independently associated with incident CHD, death, and, above all, HF. Serial determination of hs-cTnT trajectory adds clinically relevant information to baseline testing and may be useful in prognostic assessments and the targeting of prevention strategies to high-risk individuals, especially among persons with stage A or B HF. The study was published on June 8, 2016, in the journal JAMA Cardiology.
Related Links:
Johns Hopkins Bloomberg School of Public Health
Roche Diagnostics
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines